NPHC NUTRA PHARMA CORP
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1119643 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-49.0%
TTM net income YoY-255.0%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-1,017.8%
Net margin-3,370.6%
FCF margin—
EBITDA margin-1,011.4%
Returns
ROE—
ROA-731.5%
ROIC (approx.)—
Asset turnover0.22x
Leverage & solvency
Liabilities / assets3,505.0%
Debt / equity—
Current ratio0.02x
Interest coverage-68.24x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-589.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $257,612 | $246,309 |
| Cost of revenue | $183,679 | $240,557 |
| Gross profit | $196,628 | $247,323 |
| SG&A expense | — | $1.13M |
| Operating income | -$1.46M | -$878,421 |
| Interest expense | $22,870 | $21,237 |
| Pretax income | -$2.05M | -$1.29M |
| Net income | -$2.05M | -$1.29M |
| EBITDA | -$1.45M | -$870,981 |
| EPS (basic) | 0.00 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 7.78B | 7.67B |
| Balance sheet | ||
| Cash & equivalents | $12,181 | $36,447 |
| Short-term investments | $17,600 | $17,600 |
| Inventory | $19,535 | $17,696 |
| Current assets | $459,583 | $374,837 |
| PP&E, net | $25,805 | $10,402 |
| Total assets | $622,601 | $599,495 |
| Current liabilities | $17.31M | $15.27M |
| Short-term debt | $9.62M | $8.49M |
| Long-term debt | $136,644 | $140,217 |
| Total debt | $9.76M | $8.63M |
| Total liabilities | $17.45M | $15.41M |
| Shareholders' equity | -$16.83M | -$14.81M |
| Net debt | $9.75M | $8.59M |
| Shares outstanding | 7.10B | 7.10B |
| Cash flow statement | ||
| Operating cash flow | -$1.16M | -$423,959 |
| Capital expenditure | $26,052 | — |
| Free cash flow | -$1.19M | — |
| Investing cash flow | -$51,052 | $41,300 |
| Financing cash flow | $1.19M | $419,106 |
| Depreciation & amortization | $10,649 | $7,440 |
| Stock-based compensation | $26,667 | — |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.